Provided in the present disclosure is a mixture, comprising 86-89 wt % of a methionine hydroxy analog and an oligomer thereof, more than 99.95 wt % being a monomer, dimer and trimer, and the ratio of monomer:dimer:trimer by weight being 77-80:18.5-19.5:3-4; 9.2-13.5 wt % of water; and less than 0.5 wt % of ammonium sulfate and ammonium bisulfate. The viscosity of the mixture at 10° C. is lower than 200 mPa.Math.s. Further provided is a method for processing a mixture containing a methionine hydroxy analog and an oligomer thereof.

The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect. ##STR00001##

The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect. ##STR00001##

The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.

The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.

##STR00001##

The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.

##STR00001##

A compound with anti-drug resistant bacteria activity having the following formula (I):

##STR00001##

is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

A compound with anti-drug resistant bacteria activity having the following formula (I):

##STR00001##

is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

A compound with anti-drug resistant bacteria activity having the following formula (I):

##STR00001##

is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

A compound with anti-drug resistant bacteria activity having the formula (I):

##STR00001##

is disclosed. The methods of preparing the compound of formula (I) are also disclosed.